EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways

Katharine Elizabeth Joslyn, Nicholas Flinn Truver iD, Anne Marie Comi

Molecules · 2024

DOI: 10.3390/molecules29225279 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Katharine Elizabeth Joslyn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Developmental Medicine, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Sturge-Weber Syndrome, Cannabidiol, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sturge–Weber syndrome (SWS) is a rare congenital neurocutaneous disorder typically caused by a somatic mosaic mutation in R183Q GNAQ. At-risk children present at birth with a capillary malformation port-wine birthmark. The primary diagnostic characteristic of the disorder includes leptomeningeal enhancement of the brain, which demonstrates abnormal blood vessels and results in impaired venous drainage and impaired local cerebral perfusion. Impaired cerebral blood flow is complicated by seizures resulting in strokes, hemiparesis and visual field deficits, hormonal deficiencies, behavioral impairments, and intellectual disability. Therefore, anti-seizure medication in combination with low-dose aspirin is a common therapeutic treatment strategy. Recently published data indicate that the underlying mutation in endothelial cells results in the hyperactivation of downstream pathways and impairment of the blood–brain barrier. Cannabidiol (CBD) has been used to treat medically refractory seizures in SWS due to its anti-seizure, anti-inflammatory, and neuroprotective properties. Pilot research suggests that CBD improves cognitive impairment, emotional regulation, and quality of life in patients with SWS. Recent preclinical studies also suggest overlapping molecular pathways in SWS and in CBD, suggesting that CBD may be uniquely effective for SWS brain involvement. This review aims to summarize early data on CBD’s efficacy for preventing and treating epilepsy and neuro-cognitive impairments in patients with SWS, likely molecular pathways impacted, and provide insights for future translational research to improve clinical treatment for patients with SWS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sturge-Weber SyndromeCannabidiolBrainHumansAnticonvulsantsAnimalsSeizures

Stichwörter der Autor:innen

GNAQ mutationSturge–Weber syndromecannabidiolepilepsyport-wine birthmarkstroke

Substanzen

CannabidiolAnticonvulsants

Autor:innen und Institutionen

  • Department of Neurology and Developmental Medicine, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD 21205, USA.
  • Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
  • Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

ORCID-Profile: Nicholas Flinn Truver

Zitieren

APA

Joslyn, K. E., Truver, N. F., & Comi, A. M. (2024). A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways. Molecules. https://doi.org/10.3390/molecules29225279

Vancouver

Joslyn KE, Truver NF, Comi AM. A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways. Molecules. 2024. doi:10.3390/molecules29225279

BibTeX
@article{Joslyn2024,
  author = {Joslyn, Katharine Elizabeth and Truver, Nicholas Flinn and Comi, Anne Marie},
  title = {A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29225279}
}
Kostenlos starten →